Search results
Results from the WOW.Com Content Network
An antianginal is a drug used in the treatment of angina pectoris, a symptom of ischaemic heart disease. Myocardial ischemia arises from the dysfunction of coronary macrovascular or microvascular components, leading to a compromised supply of oxygen and nutrients to the myocardium. The underlying pathophysiological mechanisms encompass a range ...
It is not recommended in people with a slow heart rate or heart failure. [12] It is believed to cause problems for the fetus if used during pregnancy. [2] It is in the non–dihydropyridine calcium channel blocker family of medications. [9] Verapamil was approved for medical use in the United States in 1981.
Trimetazidine (IUPAC: 1-(2,3,4-trimethoxybenzyl)piperazine) is a drug sold under many brand names for angina pectoris (chest pain associated with impaired blood flow to the heart). [1] Trimetazidine is described as the first cytoprotective anti- ischemic agent developed and marketed by Laboratoires Servier (France).
Ranolazine was approved by the FDA in January 2006, for the treatment of patients with chronic angina as a second-line treatment in addition to other drugs. [13] In 2007 the label was updated to make ranolazine a first-line treatment, alone or with other drugs. [13] In April 2008 ranolazine was approved by the European EMEA for use in angina. [25]
In clinical studies, about 1% of all patients had to discontinue the drug because of these sensations, which occurred on average 40 days after the drug was started. [ 6 ] In a large clinical trial, bradycardia (unusually slow heart rate) occurred in 2% and 5% of patients taking ivabradine at doses of 7.5 and 10 mg respectively (compared to 4.3% ...
9. “I CAN’T TAKE MY EYES OFF OF YOU” BY LAURYN HILL. Best lyrics: “You're just too good to be true/Can't take my eyes off you/You'd be like heaven to touch (Heaven to touch)/I wanna hold ...
For premium support please call: 800-290-4726 more ways to reach us
Perhexiline (Pexsig) is a prophylactic antianginal agent used primarily in Australia and New Zealand. Perhexiline is thought to act by inhibiting mitochondrial carnitine palmitoyltransferase-1 . This shifts myocardial metabolism from fatty acid to glucose utilisation which results in increased ATP production for the same O 2 consumption and ...